All In Biotech

Drug Trial Radar · NCT04420975

Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma

A Phase I Study of Nivolumab and Intratumoral BO 112 for Resectable Soft Tissue Sarcoma

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

14

Actual

Start

Oct 14, 2020

Primary completion

Nov 12, 2026

Study completion Nov 12, 2026

Sponsor

Lead sponsor
Jonsson Comprehensive Cancer CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Cancer Institute (NCI); Highlight Therapeutics
First posted
Jun 9, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase I trial studies the side effects of BO-112 when given together with nivolumab before surgery in treating patients with soft tissue sarcoma that can be removed by surgery (resectable). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Immunotherapy with BO-112, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Giving nivolumab and BO-112 before surgery may work better in treating patients with soft tissue sarcoma compared to nivolumab alone.

Conditions

  • Leiomyosarcoma
  • Malignant Peripheral Nerve Sheath Tumor
  • Myxofibrosarcoma
  • Pleomorphic Rhabdomyosarcoma
  • Resectable Dedifferentiated Liposarcoma
  • Resectable Soft Tissue Sarcoma
  • Resectable Undifferentiated Pleomorphic Sarcoma
  • Soft Tissue Fibrosarcoma
  • Spindle Cell Sarcoma
  • Stage I Retroperitoneal Sarcoma AJCC (American Joint Committee on Cancer) v8
  • Stage I Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8
  • Stage IA Retroperitoneal Sarcoma AJCC v8
  • Stage IA Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8
  • Stage IB Retroperitoneal Sarcoma AJCC v8
  • Stage IB Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8
  • Stage II Retroperitoneal Sarcoma AJCC v8
  • Stage II Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8
  • Stage III Retroperitoneal Sarcoma AJCC v8
  • Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8
  • Stage IIIA Retroperitoneal Sarcoma AJCC v8
  • Stage IIIA Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8
  • Stage IIIB Retroperitoneal Sarcoma AJCC v8
  • Stage IIIB Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8
  • Storiform-Pleomorphic Malignant Fibrous Histiocytoma
  • Synovial Sarcoma
  • Undifferentiated High Grade Pleomorphic Sarcoma of Bone
  • Undifferentiated Pleomorphic Sarcoma
  • Undifferentiated Pleomorphic Sarcoma With Osteoclast-Like Giant Cells
  • Undifferentiated Pleomorphic Sarcoma, Inflammatory Variant
  • Undifferentiated Spindle Cell Sarcoma

Interventions

  • Definitive Surgical ResectionProcedure

    Undergo definitive surgical resection

  • Nanoplexed Poly I:C BO-112Biological

    Given intratumorally

  • NivolumabBiological

    Given IV

  • Radiation TherapyRadiation

    Undergo radiation therapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse events (AEs)Time frame: study enrollment through 100 days after the last dose of study drug

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • UCLA / Jonsson Comprehensive Cancer Center

    Los Angeles, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.